Braveheart Bio (BRVE) continues to be a primary target for short sellers, with Ortex data showing short interest as a percentage of free float rising to 43.5% this week, up from 36.8%. The stock has faced significant downward pressure, hitting all-time lows on Thursday before a modest recovery on Friday following Phase 2 data for its cardiac myosin inhibitor. Despite the positive clinical news, the expansion of days-to-cover from 9.9 to 12.5 indicates that the bearish position is becoming increasingly entrenched and potentially more difficult to unwind.
Signal data sourced from TipRanks. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.